Cargando…

Clinical use of biomarkers of survival in pulmonary fibrosis

BACKGROUND: Biologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis, more specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since treatment carries a potential risk for adverse events. These decisions are mad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomeer, Michiel, Grutters, Jan C, Wuyts, Wim A, Willems, Stijn, Demedts, Maurits G
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907324/ https://www.ncbi.nlm.nih.gov/pubmed/20584284 http://dx.doi.org/10.1186/1465-9921-11-89

Ejemplares similares

Towards Treatable Traits for Pulmonary Fibrosis
por: Hoffman, Thijs W., et al.
Publicado: (2022)

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
por: Stijn, Willems, et al.
Publicado: (2013)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis
por: Wijsenbeek, Marlies S., et al.
Publicado: (2015)

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis
por: Platenburg, Mark G. J. P., et al.
Publicado: (2023)

Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
por: Behr, Jürgen, et al.
Publicado: (2009)

Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models
por: Wuyts, Wim A., et al.
Publicado: (2014)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
por: Goos, Tinne, et al.
Publicado: (2021)

Care programs and their components for patients with idiopathic pulmonary fibrosis: a systematic review
por: Delameillieure, Anouk, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management
por: van Cleemput, Johan, et al.
Publicado: (2018)

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes
por: Delameillieure, Anouk, et al.
Publicado: (2022)

Patients’ and healthcare professionals’ perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study
por: Delameillieure, Anouk, et al.
Publicado: (2021)

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis
por: McDonough, John E., et al.
Publicado: (2018)

Behavioural and psychological patterns of patients with idiopathic pulmonary fibrosis: a prospective study
por: Delameillieure, Anouk, et al.
Publicado: (2022)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

Clinical Predictors of Survival in Idiopathic Pulmonary Fibrosis
por: Kim, Ji Hye, et al.
Publicado: (2012)

Predominant dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: to be distinguished from idiopathic pulmonary fibrosis
por: Slabbynck, Hans, et al.
Publicado: (2017)

Blood Biomarkers in Idiopathic Pulmonary Fibrosis
por: Guiot, Julien, et al.
Publicado: (2017)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Mesenchymal cell survival in airway and interstitial pulmonary fibrosis
por: Bonner, James C
Publicado: (2010)

Macrophage-Derived Biomarkers of Idiopathic Pulmonary Fibrosis
por: Bargagli, E., et al.
Publicado: (2011)

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
por: Hoffman, Thijs W., et al.
Publicado: (2023)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
por: Delanote, Isabelle, et al.
Publicado: (2016)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis
por: Kaarteenaho, Riitta, et al.
Publicado: (2015)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema
por: Demedts, Ingel K, et al.
Publicado: (2006)

Association between Variations in Cell Cycle Genes and Idiopathic Pulmonary Fibrosis
por: Korthagen, Nicoline M., et al.
Publicado: (2012)

Vibrotactile feedback as a tool to improve motor learning and sports performance: a systematic review
por: van Breda, Eric, et al.
Publicado: (2017)

Establishing a Diagnosis of Pulmonary Sarcoidosis
por: Grutters, Jan C.
Publicado: (2023)

Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
por: Hayton, Conal, et al.
Publicado: (2019)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)
por: Xu, Feng, et al.
Publicado: (2021)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
por: Wuyts, Wim A., et al.
Publicado: (2022)

The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis
por: van Batenburg, Aernoud A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_29o5m61vfd53a67btrjed6h3pi